Warning! GuruFocus detected
4 Severe warning signs
with 1OT.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Ovid Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US6904691010
Description
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.6 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | -0.24 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -4.47 | |||||
| Beneish M-Score | -1.94 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -86.2 | |||||
| 3-Year Book Growth Rate | -27.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -21.33 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -27.47 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 19.58 | |||||
| 9-Day RSI | 22.8 | |||||
| 14-Day RSI | 25.03 | |||||
| 3-1 Month Momentum % | -48.02 | |||||
| 6-1 Month Momentum % | -53.77 | |||||
| 12-1 Month Momentum % | -83.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.32 | |||||
| Quick Ratio | 5.32 | |||||
| Cash Ratio | 5.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.3 | |||||
| Shareholder Yield % | 5.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -10933.04 | |||||
| Net Margin % | -4669.97 | |||||
| FCF Margin % | -9927.39 | |||||
| ROE % | -33.08 | |||||
| ROA % | -22.46 | |||||
| ROIC % | -163.2 | |||||
| 3-Year ROIIC % | -551.59 | |||||
| ROC (Joel Greenblatt) % | -443.46 | |||||
| ROCE % | -58.17 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 39.06 | |||||
| PB Ratio | 0.28 | |||||
| Price-to-Tangible-Book | 0.28 | |||||
| EV-to-EBIT | 0.29 | |||||
| EV-to-Forward-EBIT | -1.22 | |||||
| EV-to-EBITDA | 0.29 | |||||
| EV-to-Revenue | -31.73 | |||||
| EV-to-Forward-Revenue | 3.22 | |||||
| EV-to-FCF | 0.33 | |||||
| Price-to-GF-Value | 0.27 | |||||
| Price-to-Net-Current-Asset-Value | 0.61 | |||||
| Price-to-Net-Cash | 0.67 | |||||
| Earnings Yield (Greenblatt) % | 341.65 | |||||
| FCF Yield % | -272.74 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ovid Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.522 | ||
| EPS (TTM) (€) | -0.349 | ||
| Beta | 0.83 | ||
| 3-Year Sharpe Ratio | -0.46 | ||
| 3-Year Sortino Ratio | -0.56 | ||
| Volatility % | 101.37 | ||
| 14-Day RSI | 25.03 | ||
| 14-Day ATR (€) | 0.024105 | ||
| 20-Day SMA (€) | 0.3615 | ||
| 12-1 Month Momentum % | -83.57 | ||
| 52-Week Range (€) | 0.242 - 3.08 | ||
| Shares Outstanding (Mil) | 71.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ovid Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ovid Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ovid Therapeutics Inc Frequently Asked Questions
What is Ovid Therapeutics Inc(STU:1OT)'s stock price today?
The current price of STU:1OT is €0.24. The 52 week high of STU:1OT is €3.08 and 52 week low is €0.24.
When is next earnings date of Ovid Therapeutics Inc(STU:1OT)?
The next earnings date of Ovid Therapeutics Inc(STU:1OT) is 2025-05-14 Est..
Does Ovid Therapeutics Inc(STU:1OT) pay dividends? If so, how much?
Ovid Therapeutics Inc(STU:1OT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers